About 14% of diabetic patients would turn to basal insuline therapy with glargine insuline (31% of those who receive insulin), with the potential benefit of controlling their glycemia in the same way or better with one daily injection and with fewer nocturnal hypoglycemias, thus improving their quality of life. However, the lack of information about glargine insulin s long-term effcicacy and safety, and specially its high cost, may limit its use.